N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase

Jeremy S. Francis, Ireneusz Wojtas, Vladimir Markov, Steven J. Gray, Thomas J. McCown, R. Jude Samulski, Larissa T. Bilaniuk, Dah Jyuu Wang, Darryl C. De Vivo, Christopher G. Janson, Paola Leone

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Breakdown of neuro-glial N-acetyl-aspartate (NAA) metabolism results in the failure of developmental myelination, manifest in the congenital pediatric leukodystrophy Canavan disease caused by mutations to the sole NAA catabolizing enzyme aspartoacylase. Canavan disease is a major point of focus for efforts to define NAA function, with available evidence suggesting NAA serves as an acetyl donor for fatty acid synthesis during myelination. Elevated NAA is a diagnostic hallmark of Canavan disease, which contrasts with a broad spectrum of alternative neurodegenerative contexts in which levels of NAA are inversely proportional to pathological progression. Recently generated data in the nur7 mouse model of Canavan disease suggests loss of aspartoacylase function results in compromised energetic integrity prior to oligodendrocyte death, abnormalities in myelin content, spongiform degeneration, and motor deficit. The present study utilized a next-generation “oligotropic” adeno-associated virus vector (AAV-Olig001) to quantitatively assess the impact of aspartoacylase reconstitution on developmental myelination. AAV-Olig001-aspartoacylase promoted normalization of NAA, increased bioavailable acetyl-CoA, and restored energetic balance within a window of postnatal development preceding gross histopathology and deteriorating motor function. Long-term effects included increased oligodendrocyte numbers, a global increase in myelination, reversal of vacuolation, and rescue of motor function. Effects on brain energy observed following AAV-Olig001-aspartoacylase gene therapy are shown to be consistent with a metabolic profile observed in mild cases of Canavan disease, implicating NAA in the maintenance of energetic integrity during myelination via oligodendroglial aspartoacylase.

Original languageEnglish (US)
Pages (from-to)323-334
Number of pages12
JournalNeurobiology of Disease
Volume96
DOIs
StatePublished - Dec 1 2016

Fingerprint

Canavan Disease
Oligodendroglia
Dependovirus
Acetyl Coenzyme A
Metabolome
N-acetylaspartate
aspartoacylase
Myelin Sheath
Neuroglia
Genetic Therapy
Fatty Acids
Maintenance
Pediatrics
Mutation
Brain
Enzymes

Keywords

  • Aspartoacylase
  • Canavan disease
  • Energy
  • Myelination
  • N-acetylaspartate

ASJC Scopus subject areas

  • Neurology

Cite this

N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. / Francis, Jeremy S.; Wojtas, Ireneusz; Markov, Vladimir; Gray, Steven J.; McCown, Thomas J.; Samulski, R. Jude; Bilaniuk, Larissa T.; Wang, Dah Jyuu; De Vivo, Darryl C.; Janson, Christopher G.; Leone, Paola.

In: Neurobiology of Disease, Vol. 96, 01.12.2016, p. 323-334.

Research output: Contribution to journalArticle

Francis, JS, Wojtas, I, Markov, V, Gray, SJ, McCown, TJ, Samulski, RJ, Bilaniuk, LT, Wang, DJ, De Vivo, DC, Janson, CG & Leone, P 2016, 'N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase', Neurobiology of Disease, vol. 96, pp. 323-334. https://doi.org/10.1016/j.nbd.2016.10.001
Francis, Jeremy S. ; Wojtas, Ireneusz ; Markov, Vladimir ; Gray, Steven J. ; McCown, Thomas J. ; Samulski, R. Jude ; Bilaniuk, Larissa T. ; Wang, Dah Jyuu ; De Vivo, Darryl C. ; Janson, Christopher G. ; Leone, Paola. / N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. In: Neurobiology of Disease. 2016 ; Vol. 96. pp. 323-334.
@article{c81e7e53e95348b3997caa0ec4967f48,
title = "N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase",
abstract = "Breakdown of neuro-glial N-acetyl-aspartate (NAA) metabolism results in the failure of developmental myelination, manifest in the congenital pediatric leukodystrophy Canavan disease caused by mutations to the sole NAA catabolizing enzyme aspartoacylase. Canavan disease is a major point of focus for efforts to define NAA function, with available evidence suggesting NAA serves as an acetyl donor for fatty acid synthesis during myelination. Elevated NAA is a diagnostic hallmark of Canavan disease, which contrasts with a broad spectrum of alternative neurodegenerative contexts in which levels of NAA are inversely proportional to pathological progression. Recently generated data in the nur7 mouse model of Canavan disease suggests loss of aspartoacylase function results in compromised energetic integrity prior to oligodendrocyte death, abnormalities in myelin content, spongiform degeneration, and motor deficit. The present study utilized a next-generation “oligotropic” adeno-associated virus vector (AAV-Olig001) to quantitatively assess the impact of aspartoacylase reconstitution on developmental myelination. AAV-Olig001-aspartoacylase promoted normalization of NAA, increased bioavailable acetyl-CoA, and restored energetic balance within a window of postnatal development preceding gross histopathology and deteriorating motor function. Long-term effects included increased oligodendrocyte numbers, a global increase in myelination, reversal of vacuolation, and rescue of motor function. Effects on brain energy observed following AAV-Olig001-aspartoacylase gene therapy are shown to be consistent with a metabolic profile observed in mild cases of Canavan disease, implicating NAA in the maintenance of energetic integrity during myelination via oligodendroglial aspartoacylase.",
keywords = "Aspartoacylase, Canavan disease, Energy, Myelination, N-acetylaspartate",
author = "Francis, {Jeremy S.} and Ireneusz Wojtas and Vladimir Markov and Gray, {Steven J.} and McCown, {Thomas J.} and Samulski, {R. Jude} and Bilaniuk, {Larissa T.} and Wang, {Dah Jyuu} and {De Vivo}, {Darryl C.} and Janson, {Christopher G.} and Paola Leone",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.nbd.2016.10.001",
language = "English (US)",
volume = "96",
pages = "323--334",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase

AU - Francis, Jeremy S.

AU - Wojtas, Ireneusz

AU - Markov, Vladimir

AU - Gray, Steven J.

AU - McCown, Thomas J.

AU - Samulski, R. Jude

AU - Bilaniuk, Larissa T.

AU - Wang, Dah Jyuu

AU - De Vivo, Darryl C.

AU - Janson, Christopher G.

AU - Leone, Paola

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Breakdown of neuro-glial N-acetyl-aspartate (NAA) metabolism results in the failure of developmental myelination, manifest in the congenital pediatric leukodystrophy Canavan disease caused by mutations to the sole NAA catabolizing enzyme aspartoacylase. Canavan disease is a major point of focus for efforts to define NAA function, with available evidence suggesting NAA serves as an acetyl donor for fatty acid synthesis during myelination. Elevated NAA is a diagnostic hallmark of Canavan disease, which contrasts with a broad spectrum of alternative neurodegenerative contexts in which levels of NAA are inversely proportional to pathological progression. Recently generated data in the nur7 mouse model of Canavan disease suggests loss of aspartoacylase function results in compromised energetic integrity prior to oligodendrocyte death, abnormalities in myelin content, spongiform degeneration, and motor deficit. The present study utilized a next-generation “oligotropic” adeno-associated virus vector (AAV-Olig001) to quantitatively assess the impact of aspartoacylase reconstitution on developmental myelination. AAV-Olig001-aspartoacylase promoted normalization of NAA, increased bioavailable acetyl-CoA, and restored energetic balance within a window of postnatal development preceding gross histopathology and deteriorating motor function. Long-term effects included increased oligodendrocyte numbers, a global increase in myelination, reversal of vacuolation, and rescue of motor function. Effects on brain energy observed following AAV-Olig001-aspartoacylase gene therapy are shown to be consistent with a metabolic profile observed in mild cases of Canavan disease, implicating NAA in the maintenance of energetic integrity during myelination via oligodendroglial aspartoacylase.

AB - Breakdown of neuro-glial N-acetyl-aspartate (NAA) metabolism results in the failure of developmental myelination, manifest in the congenital pediatric leukodystrophy Canavan disease caused by mutations to the sole NAA catabolizing enzyme aspartoacylase. Canavan disease is a major point of focus for efforts to define NAA function, with available evidence suggesting NAA serves as an acetyl donor for fatty acid synthesis during myelination. Elevated NAA is a diagnostic hallmark of Canavan disease, which contrasts with a broad spectrum of alternative neurodegenerative contexts in which levels of NAA are inversely proportional to pathological progression. Recently generated data in the nur7 mouse model of Canavan disease suggests loss of aspartoacylase function results in compromised energetic integrity prior to oligodendrocyte death, abnormalities in myelin content, spongiform degeneration, and motor deficit. The present study utilized a next-generation “oligotropic” adeno-associated virus vector (AAV-Olig001) to quantitatively assess the impact of aspartoacylase reconstitution on developmental myelination. AAV-Olig001-aspartoacylase promoted normalization of NAA, increased bioavailable acetyl-CoA, and restored energetic balance within a window of postnatal development preceding gross histopathology and deteriorating motor function. Long-term effects included increased oligodendrocyte numbers, a global increase in myelination, reversal of vacuolation, and rescue of motor function. Effects on brain energy observed following AAV-Olig001-aspartoacylase gene therapy are shown to be consistent with a metabolic profile observed in mild cases of Canavan disease, implicating NAA in the maintenance of energetic integrity during myelination via oligodendroglial aspartoacylase.

KW - Aspartoacylase

KW - Canavan disease

KW - Energy

KW - Myelination

KW - N-acetylaspartate

UR - http://www.scopus.com/inward/record.url?scp=84991221445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991221445&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2016.10.001

DO - 10.1016/j.nbd.2016.10.001

M3 - Article

VL - 96

SP - 323

EP - 334

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -